131 related articles for article (PubMed ID: 34129153)
21. Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in
Bai X; Shaheen A; Grieco C; d'Arienzo PD; Mina F; Czapla JA; Lawless AR; Bongiovanni E; Santaniello U; Zappi H; Dulak D; Williamson A; Lee R; Gupta A; Li C; Si L; Ubaldi M; Yamazaki N; Ogata D; Johnson R; Park BC; Jung S; Madonna G; Hochherz J; Umeda Y; Nakamura Y; Gebhardt C; Festino L; Capone M; Ascierto PA; Johnson DB; Lo SN; Long GV; Menzies AM; Namikawa K; Mandala M; Guo J; Lorigan P; Najjar YG; Haydon A; Quaglino P; Boland GM; Sullivan RJ; Furness AJS; Plummer R; Flaherty KT
EClinicalMedicine; 2023 Nov; 65():102290. PubMed ID: 37965433
[TBL] [Abstract][Full Text] [Related]
22. Evaluating cost benefits of combination therapies for advanced melanoma.
Jensen IS; Zacherle E; Blanchette CM; Zhang J; Yin W
Drugs Context; 2016; 5():212297. PubMed ID: 27540409
[TBL] [Abstract][Full Text] [Related]
23. Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany.
Wahler S; Müller A; Koll C; Seyed-Abbaszadeh P; Von Der Schulenburg JM
J Mark Access Health Policy; 2020 Dec; 9(1):1861804. PubMed ID: 33456727
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant therapy for stage II melanoma: the need for further studies.
Lee R; Mandala M; Long GV; Eggermont AMM; van Akkooi ACJ; Sandhu S; Garbe C; Lorigan P
Eur J Cancer; 2023 Aug; 189():112914. PubMed ID: 37301717
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland.
Favre-Bulle A; Huang M; Haiderali A; Bhadhuri A
Pharmacoecon Open; 2024 Jan; 8(1):91-101. PubMed ID: 37999854
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of an orphan drug tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing.
Luo S; Xie C; Lin N; Lin D; Gu D; Lin S; Huang X; Xu X; Weng X
Melanoma Res; 2023 Dec; 33(6):525-531. PubMed ID: 37650713
[TBL] [Abstract][Full Text] [Related]
27. Cost-Benefit Implication of Gene Expression Profiling and Adjuvant Therapy in Stage IIIA Melanoma.
Hu Y; Briggs A; Marchetti MA; Ariyan CE; Coit DG; Bartlett EK
J Am Coll Surg; 2020 Nov; 231(5):547-554.e1. PubMed ID: 32889093
[TBL] [Abstract][Full Text] [Related]
28. Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States.
Huo G; Song Y; Liu W; Cao X; Chen P
Front Pharmacol; 2024; 15():1300183. PubMed ID: 38606181
[No Abstract] [Full Text] [Related]
29. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma.
Menzies AM; Lo SN; Saw RPM; Gonzalez M; Ch'ng S; Nieweg OE; Shannon KF; Ferguson PM; Lee J; Emmett L; Kapoor R; Rawson RV; Stretch JR; Thompson JF; Spillane AJ; Rizos H; Scolyer RA; Long GV
Ann Oncol; 2024 May; ():. PubMed ID: 38754780
[TBL] [Abstract][Full Text] [Related]
30. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Kennedy OJ; Kicinski M; Valpione S; Gandini S; Suciu S; Blank CU; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Boers-Sonderen M; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; van Akkooi ACJ; Robert C; Eggermont AMM; Lorigan P; Mandala M
Eur J Cancer; 2023 Aug; 189():112900. PubMed ID: 37277264
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial.
Ten Ham RMT; Rohaan MW; Jedema I; Kessels R; Stegeman W; Scheepmaker W; Nuijen B; Nijenhuis C; Lindenberg M; Borch TH; Monberg T; Donia M; Marie Svane I; van Harten W; Haanen J; Retel VP
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38531663
[TBL] [Abstract][Full Text] [Related]
32. Perioperative therapy of melanoma: Adjuvant or neoadjuvant treatment.
Rutkowski P; Mandala M
Eur J Surg Oncol; 2024 Mar; 50(3):107969. PubMed ID: 38342039
[TBL] [Abstract][Full Text] [Related]
33. Long-term drug costs per life-month gained associated with first-line treatments for unresectable or metastatic melanoma.
Liu JS; Rao S
Exp Hematol Oncol; 2015; 5():9. PubMed ID: 27069772
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting.
Lauren B; Ostvar S; Silver E; Ingram M; Oh A; Kumble L; Laszkowska M; Chu JN; Hershman DL; Manji G; Neugut AI; Hur C
J Oncol; 2020; 2020():2198960. PubMed ID: 32148492
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis.
Zhu Y; Liu K; Zhu H; Wu H
Therap Adv Gastroenterol; 2023; 16():17562848231207200. PubMed ID: 37928895
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness of Diffusion-Weighted Magnetic Resonance Imaging Versus Second-Look Surgery in Treating Cholesteatoma: A Modeling Study.
Bu DD; Schwam ZG; Wanna GB; Perez E; Cosetti MK
Otol Neurotol; 2024 Feb; 45(2):163-168. PubMed ID: 38206064
[TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness of Adjuvant Immunotherapy With Cytokine-Induced Killer Cell for Hepatocellular Carcinoma Based on a Randomized Controlled Trial and Real-World Data.
Cho JY; Kwon SH; Lee EK; Lee JH; Kim HL
Front Oncol; 2021; 11():728740. PubMed ID: 34926248
[TBL] [Abstract][Full Text] [Related]
38. Optimal systemic therapy for high-risk resectable melanoma.
Eggermont AMM; Hamid O; Long GV; Luke JJ
Nat Rev Clin Oncol; 2022 Jul; 19(7):431-439. PubMed ID: 35468949
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness Treatment of a BRAF-ZKSCAN5 Fusion Gene Melanoma Case with Dabrafenib/Trametinib.
Kato H; Kano S; Yasui Y; Nojiri Y; Yoshimitsu M; Nakamura M; Morita A
Case Rep Oncol; 2023; 16(1):1007-1012. PubMed ID: 37900828
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC.
Rieger C; Schlüchtermann J; Storz E; Kastner L; Pfister D; Heidenreich A
BJU Int; 2024 Mar; ():. PubMed ID: 38491799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
